Story thread · 5 reports / 5 sources
J&J Joins Immune Reset Race, Paying $785M to Partner on Sail Bio Cell Therapy
medcitynews.com · 12d
How the coverage leans
Across 5 sources · syndicated copies counted once
Johnson & Johnson also gains an exclusive option to acquire Sail Biosciences for $2.85 billion. The deal puts J&J in the mix of pharmaceutical companies developing next-generation cell therapies for applications in autoimmune diseases. The post J&J Joins Immune Reset Race, Paying $785M to Partner on Sail Bio Cell Therapy appeared first on MedCity News .
First report: J&J Gains Option to Buy Sail Biomedicines for $2.6 Billion — bloomberg.com, 12d
The coverage
- J&J nabs option to buy ‘in vivo’ CAR-T maker Sail for nearly $2.6B
biopharmadive.com · 12d
- J&J lines up $2.58B option to buy Sail, Flagship's in vivo CAR-T biotech
endpts.com · 12d
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.